Ayahuasca: What Healthcare Providers Need to Know
- PMID: 34060770
- DOI: 10.1097/JAN.0000000000000405
Ayahuasca: What Healthcare Providers Need to Know
Abstract
Ayahuasca is a pan-Amazonian botanical hallucinogenic decoction made from a mixture of the bark of the Banisteriopsis caapi plant, containing a monoamine oxidase inhibitor, and Psychotria viridis (Rubiaceae) or Diplopterys cabrerana shrubs containing a serotonergic 2A receptor agonist, N,N-dimethyltryptamine, a powerful psychoactive substance. Ayahuasca is a traditional psychoactive sacrament that has been used for shamanic ceremonies for centuries. Ayahuasca is acclaimed for spiritual and psychotherapeutic benefits and is gaining popularity in the United States. Potential risks involved with usage of this hallucinogenic drug include psychotic episodes related to N,N-dimethyltryptamine and serotonin syndrome, which can be potentially life threatening. The consequences of ayahuasca use remain uncertain because of poor quality control, unpredictability, and polydrug interactions. Nurses, advanced practice nurses, and other healthcare providers working in outpatient settings, hospitals, and treatment centers need to be familiar with the pharmacology, possible drug interactions, and management for ayahuasca ingestion for optimal decision making. Nurses are well positioned to facilitate understanding and to advise and educate the public about the potential risks associated with ayahuasca ingestion.
Copyright © 2021 International Nurses Society on Addictions.
Conflict of interest statement
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article.
Similar articles
-
Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.Curr Neuropharmacol. 2019;17(2):108-128. doi: 10.2174/1570159X16666180125095902. Curr Neuropharmacol. 2019. PMID: 29366418 Free PMC article. Review.
-
Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?Ment Health Clin. 2018 Mar 23;7(1):39-45. doi: 10.9740/mhc.2017.01.039. eCollection 2017 Jan. Ment Health Clin. 2018. PMID: 29955496 Free PMC article.
-
Ayahuasca Exposure: Descriptive Analysis of Calls to US Poison Control Centers from 2005 to 2015.J Med Toxicol. 2017 Sep;13(3):245-248. doi: 10.1007/s13181-016-0593-1. Epub 2016 Nov 28. J Med Toxicol. 2017. PMID: 27896660 Free PMC article.
-
Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact.Pharmaceuticals (Basel). 2020 Oct 23;13(11):334. doi: 10.3390/ph13110334. Pharmaceuticals (Basel). 2020. PMID: 33114119 Free PMC article. Review.
-
Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.Drug Test Anal. 2012 Jul-Aug;4(7-8):610-6. doi: 10.1002/dta.1344. Epub 2012 Apr 19. Drug Test Anal. 2012. PMID: 22514127
References
-
- American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Author.
-
- Azarius. (n.d.). Ayahuasca-encyclopedia. Retrieved October 20, 2020, from https://azarius.net/encyclopedia/4/ayahuasca/
-
- Barbosa P. C., Mizumoto S., Bogenschutz M. P., Strassman R. J. (2012). Health status of ayahuasca users. Drug Testing and Analysis, 4(7–8), 601–609. https://doi.org/10.1002/dta.1383 - DOI
-
- Barrett F. S., Schlienz N. J., Lembeck N., Waqas M., Vandrey R. (2018). "Hallucinations" following acute cannabis dosing: A case report and comparison to other hallucinogenic drugs. Cannabis and Cannabinoid Research, 3(1), 85–93. https://doi.org/10.1089/can.2017.0052 - DOI
-
- Bauer I. L. (2018). Ayahuasca: A risk for travelers?Travel Medicine and Infectious Disease, 21, 74–76. https://doi.org/10.1016/j.tmaid.2018.01.002 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources